Clinical Trial

Study Of Cadonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated December 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
Cadonilimab（AK104）is a humanized IgG1 bispecific antibody that targets PD-1 and CTLA-4. This is a single-arm, multicenter, open-label, phase II study, the purpose of this study is to evaluate the efficacy and safety of Cadonilimab plus radiotherapy in participants with locally advanced cervical cancer who do not tolerate chemotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-01-15.
Trial Details
NCT Number NCT05687851
Lead Sponsor Chongqing University Cancer Hospital
Collaborators: Liaoning Cancer Hospital & Institute, Henan Cancer Hospital, Fujian Cancer Hospital
Conditions Locally Advanced Cervical Cancer
Enrollment 33 participants
Start Date 2022-12-29
Primary Completion 2024-12-30 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-09-19